Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells
- PMID: 2007856
- PMCID: PMC2190812
- DOI: 10.1084/jem.173.4.881
Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells
Abstract
The gp120 envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) is a dominant target against which the host's humoral immune response is directed. Unfortunately, gp120 proteins from different isolates of HIV are antigenically distinct, complicating the use of the envelope glycoprotein in vaccines designed to prevent acquired immunodeficiency syndrome. Using an enzyme-linked immunosorbent spot assay (ELISA), BALB/c mice immunized and boosted with recombinant purified gp120 were studied at the single cell level for their humoral immune response to HIV-1 envelope proteins. Approximately 90% of responding B cells produced antibodies reactive with the immunizing form of gp120 but not with gp120s from other strains of HIV. A novel sandwich ELISA was then used to analyze the frequency with which individual in vivo activated B cells produced antibodies that crossreacted with heterologous gp120s. Repeated immunizations with a single gp120 or with a mixture of different gp120s resulted in the activation of primarily mono-specific (noncrossreactive) B cells. In contrast, the sequential immunization of mice with recombinant purified envelope proteins from different strains of HIV (IIIB, SF2, and Zr6) induced the selective expansion of B cells producing highly crossreactive antibodies.
Similar articles
-
Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.Clin Diagn Lab Immunol. 1996 Jul;3(4):378-86. doi: 10.1128/cdli.3.4.378-386.1996. Clin Diagn Lab Immunol. 1996. PMID: 8807200 Free PMC article. Clinical Trial.
-
Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.J Virol. 2016 Nov 28;90(24):10993-11006. doi: 10.1128/JVI.01403-16. Print 2016 Dec 15. J Virol. 2016. PMID: 27630234 Free PMC article.
-
Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120).Vaccine. 1989 Oct;7(5):465-73. doi: 10.1016/0264-410x(89)90164-3. Vaccine. 1989. PMID: 2554608
-
The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.Virology. 1998 Nov 10;251(1):59-70. doi: 10.1006/viro.1998.9392. Virology. 1998. PMID: 9813203
-
HIV-1 gp120: a novel viral B cell superantigen.Int Rev Immunol. 1997;14(4):325-38. doi: 10.3109/08830189709116523. Int Rev Immunol. 1997. PMID: 9186784 Review.
Cited by
-
IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells.Commun Biol. 2018 Sep 5;1:134. doi: 10.1038/s42003-018-0131-6. eCollection 2018. Commun Biol. 2018. PMID: 30272013 Free PMC article.
-
Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Adv Immunol. 2017;134:235-352. doi: 10.1016/bs.ai.2017.01.004. Adv Immunol. 2017. PMID: 28413022 Free PMC article. Review.
-
Neutralization-Enhancing RF Antibodies for HIV Vaccines.Front Immunol. 2014 Dec 16;5:634. doi: 10.3389/fimmu.2014.00634. eCollection 2014. Front Immunol. 2014. PMID: 25566247 Free PMC article. Review. No abstract available.
-
Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.Vaccine. 2014 Nov 12;32(48):6527-36. doi: 10.1016/j.vaccine.2014.08.065. Epub 2014 Sep 20. Vaccine. 2014. PMID: 25245933 Free PMC article.
-
Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins.Viral Immunol. 2016 Jan-Feb;29(1):64-70. doi: 10.1089/vim.2015.0078. Epub 2015 Nov 6. Viral Immunol. 2016. PMID: 26544795 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources